NCT02183415View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS as Tablet in Patients With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

January 31, 2006

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

BI 1356 BS, low dose

DRUG

BI 1356 BS, medium dose

DRUG

BI 1356 BS, high dose

DRUG

Placebo

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY